Key Points
- Roivant Sciences CEO Eric Venker sold 200,000 shares on May 22 at an average price of $30.27, totaling about $6.05 million. The sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards.
- Venker has sold 200,000 shares three times recently, including transactions in April and March at lower prices, indicating a steady pattern of insider selling.
- Roivant shares closed around $29.96, and the company recently reported quarterly EPS of $0.28, beating expectations, while analysts remain broadly positive with a Moderate Buy consensus and an average price target of $33.05.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the business's stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $30.27, for a total value of $6,054,000.00. Following the sale, the chief executive officer owned 1,613,063 shares of the company's stock, valued at $48,827,417.01. The trade was a 11.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Eric Venker also recently made the following trade(s):
- On Monday, April 20th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $29.59, for a total value of $5,918,000.00.
- On Tuesday, March 17th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $28.24, for a total value of $5,648,000.00.
Roivant Sciences Stock Performance
Shares of NASDAQ:ROIV opened at $29.96 on Friday. Roivant Sciences Ltd. has a 1 year low of $10.59 and a 1 year high of $32.79. The stock has a market capitalization of $21.44 billion, a P/E ratio of -49.93 and a beta of 1.14. The stock has a 50-day simple moving average of $28.46 and a 200-day simple moving average of $25.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million during the quarter, compared to analysts' expectations of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter in the previous year, the business earned ($0.29) EPS. Analysts predict that Roivant Sciences Ltd. will post -1.06 earnings per share for the current year.
Hedge Funds Weigh In On Roivant Sciences
Institutional investors have recently made changes to their positions in the business. TD Asset Management Inc raised its position in shares of Roivant Sciences by 94.7% in the 3rd quarter. TD Asset Management Inc now owns 316,200 shares of the company's stock valued at $4,784,000 after purchasing an additional 153,800 shares in the last quarter. HighVista Strategies LLC raised its position in shares of Roivant Sciences by 61.4% in the 3rd quarter. HighVista Strategies LLC now owns 98,858 shares of the company's stock valued at $1,496,000 after purchasing an additional 37,590 shares in the last quarter. Fox Run Management L.L.C. acquired a new position in shares of Roivant Sciences in the 3rd quarter valued at approximately $877,000. Neo Ivy Capital Management raised its position in shares of Roivant Sciences by 229.6% in the 3rd quarter. Neo Ivy Capital Management now owns 237,392 shares of the company's stock valued at $3,592,000 after purchasing an additional 165,362 shares in the last quarter. Finally, Capricorn Fund Managers Ltd raised its position in shares of Roivant Sciences by 124.4% in the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company's stock valued at $9,667,000 after purchasing an additional 247,000 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the company. Piper Sandler reissued an "overweight" rating on shares of Roivant Sciences in a research report on Thursday. Guggenheim boosted their price target on Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, February 9th. HC Wainwright reissued a "buy" rating and set a $34.00 price target on shares of Roivant Sciences in a research report on Thursday. Sanford C. Bernstein assumed coverage on Roivant Sciences in a research report on Friday, March 20th. They set an "outperform" rating and a $35.00 price target on the stock. Finally, Citigroup boosted their price target on Roivant Sciences from $35.00 to $42.00 and gave the stock a "buy" rating in a research report on Thursday. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $33.05.
Check Out Our Latest Research Report on Roivant Sciences
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
